Strengthening the Growth Momentum of Daxifi® and Exploring Multi-Dimensional Cooperation Potential
Hong KongApril 23, 2026 /PRNewswire/ — Sisram Medical Ltd. (English “Sisram”; hereinafter referred to as the “Company” or “Sisram Medical”, stock code: 1696.HK, together with its subsidiaries collectively referred to as the “Group”), a globalized beauty and wellness group dedicated to building a customer-oriented ecosystem centered on energy-based devices and injectable products, today announced the signing of a strategic cooperation memorandum with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (referred to as “Fosun Pharma Industrial”) and Revance Therapeutics, Inc. (“Revance”). This memorandum initiates in-depth negotiations on the long-term strategic framework and core commercial terms surrounding Daxifi®, laying a solid foundation for the subsequent comprehensive deepening of cooperation and efficient implementation among the three parties.
Leveraging Fosun Pharma Industrial’s extensive resource accumulation and industrial influence across the entire value chain, along with Revance’s cutting-edge technological reserves and core product R&D advantages in the injectable filler field, the Company will fully unleash its global channel layout and refined operational strengths. This will accelerate the commercialization process of Daxifi® in China, continuously expand market coverage, enhance brand influence, and drive steady sales growth. At the same time, the Company will collaborate with Revance to discuss cooperation mechanisms and related core commercial arrangements, achieving long-term sustainable development in the Chinese market. Furthermore, the three parties will actively expand the boundaries of cooperation, extending the collaboration region from Mainland China, Hong Kong, and Macau to more high-potential global markets, and explore synergistic efforts in innovative product pipelines to continuously enrich the product matrix and broaden business growth opportunities.
As the world’s first long-acting botulinum toxin type A product utilizing proprietary peptide exchange technology, Daxifi® has, since its commercial launch in China in January 2026, rapidly gained widespread recognition and praise from domestic medical aesthetics clinics and consumers due to its core advantages of fast onset, long-lasting efficacy, and safety and reliability. Its word-of-mouth effect continues to build. As of the end of the first quarter of 2026, nearly 20,000 units of Daxifi® had been shipped from warehouses, successfully covering over 100 high-end light medical aesthetics clinics. Clinical application data at the terminal level has steadily increased, fully demonstrating its broad development prospects in the Chinese botulinum toxin market and laying a solid market foundation for the deepening of this strategic cooperation.
Sisram Medical stated that this comprehensive upgrade of the strategic cooperation with Revance will accelerate the commercialization pace of Daxifi® in the Chinese market, help the Company precisely seize the development dividends of the Chinese botulinum toxin market, strengthen its core competitiveness in the injectable filler field, and drive this growth engine to continue gaining momentum. Looking ahead, the Company will adhere to a dual-drive strategy of organic growth and external expansion, deeply explore opportunities in the global medical aesthetics industry, and continuously focus on technological innovation and clinical excellence. It aims to provide safe, efficient, and trustworthy beauty and wellness solutions to consumers worldwide, contributing to the steady enhancement of the Company’s long-term value.
About Sisram Medical
Sisram Medical Ltd. (stock code: 1696.HK) is a globalized beauty and wellness group with over 25 years of professional experience in the energy-based device (EBD) field. Rooted in technological innovation and clinical excellence, the Company has built an ecosystem encompassing energy-based devices, injectable products, diagnostics, and synergistic solutions. With operations spanning more than 110 countries and regions worldwide, the Company has set a new benchmark in safe, effective, and personalized medical aesthetics care for millions of consumers globally through its award-winning products. Sisram Medical is a controlled subsidiary of Fosun Pharma, a leading healthcare industry group in China, and has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.
For more information, please visit: www.sisram-medical.com.
Forward-Looking Statements
The information conveyed in this press release contains certain statements that are or may be forward-looking in nature. These statements typically contain words such as “will,” “expect,” “believe,” “plan,” and “anticipate,” as well as words of similar meaning. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There may be other significant risks that are currently considered immaterial or not known to the Company. Such forward-looking statements are not guarantees of future performance. In light of these uncertainties, readers should not place undue reliance on such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements in light of future events or developments.